Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: Posttreatment 1-year results of three Turkish centres

Journal of Chemotherapy

Volumn 26, Issue 6, 2014, Pages 339-341

  Yamazhan, Tansu ^a   Kurtaran, Behice ^b   Pullukçu, HüSnü ^a   Yüksel, Esma ^c   Özkaya, Deniz ^c   Taşbakan, Meltem IşıKgöZ ^a   Sipahi, OğUz ReşAt ^a   Durusoy, Raika ^a   Salih Zeki Aksu, Hasan ^b  

^a EGE UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

^c Karsiyaka Devlet Hastanesi   (Turkey)

Author keywords

Chronic hepatitis B; Genotype; Pegylated interferons; Primary non responders; Secondary non responders; Treatment response

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; VIRUS DNA;

ADULT; BLOOD; FEMALE; HEPATITIS B, CHRONIC; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84920097807     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000152     Document Type: Article

References (16)

1. Sonneveld M, Janssen HL. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int. 2011;3:78–84.
2. Sonneveld M, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for the treatment of chronic hepatitis B. Curr Hepatitis Rep. 2010;9:91–8.
3. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurtaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg negative chronic hepatitis B. Hepatology. 2009;49:1141–50.
4. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933–44.
5. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection European Association for the Study of the Liver. J Hepatol. 2012;57:167–85.
6. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection European Association for the Study of the Liver. J Hepatol. 2009;50:227–42.
7. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.
8. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–9.
9. Yapalı S, Bayrakcı M, Akyıldız M, Vardar R, Günsar F, Ersöz G, et al. Hepatitis B surface antigen seroclearance rates and associated factors in chronic hepatitis B infection. J Hepatol. 2010;52:287.
10. Dikici B, Uzun H, Gözü A, Fidan M. Prevalence of hepatitis B infection among schoolchildren in southeast Turkey. Turk J Med Sci. 2009;39:289–93.
11. Karabay O, Tuna N, Esen Ş PEG-HBV Study Group. Comparative efficacy of pegylated interferons a-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol. 2012;24:1296–301.
12. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297–303.
13. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002–9.
14. Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepatitis. 2010;17:601–10.
15. Şentürk H, Baysal B, Tahan V, Zerdali H, Ö zaras R, Tabak F, et al. Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection. Dig Dis Sci. 2011;56:208–12.
16. Leblebicioglu H, Eroglu C, Members of the Hepatitis Study Group. Acute hepatitis B virus infection in Turkey: epidemiology and genotype distribution. Clin Microbiol Infect. 2004;10:537–41.